Disposition of 217 shares by Natalie Munk of Myriad Genetics at 28.12 subject to Rule 16b-3

MYGN Stock  USD 16.28  0.11  0.68%   
About 62% of Myriad Genetics' investor base is looking to short. The analysis of the overall investor sentiment regarding Myriad Genetics suggests that many traders are alarmed. Myriad Genetics' investing sentiment overview a quick insight into current market opportunities from investing in Myriad Genetics. Many technical investors use Myriad Genetics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Myriad Genetics Officer: Chief Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 217 common stock at 28.12 of Myriad Genetics by Natalie Munk on 25th of August 2024. This event was filed by Myriad Genetics with SEC on 2024-08-25. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Myriad Genetics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Myriad Genetics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Myriad Genetics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Myriad Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Myriad Genetics Historical Investor Sentiment

Investor biases related to Myriad Genetics' public news can be used to forecast risks associated with an investment in Myriad. The trend in average sentiment can be used to explain how an investor holding Myriad can time the market purely based on public headlines and social activities around Myriad Genetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Myriad Genetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Myriad Genetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Myriad Genetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Myriad Genetics.

Myriad Genetics Fundamental Analysis

We analyze Myriad Genetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Myriad Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Myriad Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Myriad Genetics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Myriad Genetics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Myriad Genetics stock to make a market-neutral strategy. Peer analysis of Myriad Genetics could also be used in its relative valuation, which is a method of valuing Myriad Genetics by comparing valuation metrics with similar companies.

Peers

Myriad Genetics Related Equities

PSNLPersonalis   5.36   
0%
100.0%
ACRSAclaris Therapeutics   5.23   
0%
97.0%
TWSTTwist Bioscience   4.27   
0%
79.0%
EXASEXACT Sciences   2.65   
0%
49.0%
GHGuardant Health   2.12   
0%
39.0%
RDNTRadNet   1.28   
0%
23.0%
QGENQiagen NV   1.18   
0%
22.0%
SHCSotera Health   1.16   
0%
21.0%
MEDPMedpace Holdings   1.12   
0%
20.0%
ILMNIllumina   0.99   
0%
18.0%
NTRANatera   0.08   
0%
1.0%
NEOGNeogen   0.21   
3.0%
0%
CSTLCastle Biosciences   0.43   
8.0%
0%
CDNACaredx   0.84   
15.0%
0%
When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:
Check out Myriad Genetics Hype Analysis, Myriad Genetics Correlation and Myriad Genetics Performance.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.28)
Revenue Per Share
9.205
Quarterly Revenue Growth
0.112
Return On Assets
(0.05)
Return On Equity
(0.16)
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.